Cargando…

A diagnostic challenge of seromucinous borderline tumor: A case report

INTRODUCTION: Magnetic resonance (MR) relaxometry provides a noninvasive predictive tool to discriminate between benign ovarian endometrioma (OE) and endometriosis-associated ovarian cancer (EAOC). Transverse relaxation rate R2 value was determined using a single-voxel, multi-echo MR sequence (HISTO...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tingting, Sumida, Daichi, Wada, Takuya, Maehana, Tomoka, Yamawaki, Aika, Sugimoto, Sumire, Kawahara, Naoki, Yoshimoto, Chiharu, Kobayashi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709009/
https://www.ncbi.nlm.nih.gov/pubmed/31145284
http://dx.doi.org/10.1097/MD.0000000000015707
_version_ 1783446109512794112
author Liu, Tingting
Sumida, Daichi
Wada, Takuya
Maehana, Tomoka
Yamawaki, Aika
Sugimoto, Sumire
Kawahara, Naoki
Yoshimoto, Chiharu
Kobayashi, Hiroshi
author_facet Liu, Tingting
Sumida, Daichi
Wada, Takuya
Maehana, Tomoka
Yamawaki, Aika
Sugimoto, Sumire
Kawahara, Naoki
Yoshimoto, Chiharu
Kobayashi, Hiroshi
author_sort Liu, Tingting
collection PubMed
description INTRODUCTION: Magnetic resonance (MR) relaxometry provides a noninvasive predictive tool to discriminate between benign ovarian endometrioma (OE) and endometriosis-associated ovarian cancer (EAOC). Transverse relaxation rate R2 value was determined using a single-voxel, multi-echo MR sequence (HISTO) by a 3T-MR system. R2 with cutoff value of 12.1 s(−1) was established to discriminate between benign and malignant tumors. PATIENT CONCERNS: We present a case of a 39-year-old woman who was initially thought to be malignant transformation of endometriosis by diagnostic MR imaging of the vascularized solid components. DIAGNOSIS: A R2 value of 42.62 s(−1) on MR relaxometry demonstrated that this case is non-malignant. INTERVENTIONS: To confirm the diagnose, left salpingo-oophorectomy by laparoscopic surgery was performed. OUTCOMES: Histopathological results revealed seromucinous borderline tumor (SMBT). Our experience suggests that preoperative MR relaxometry may be useful for discriminating “borderline (SMBT)” from “malignancy (EAOC).” Furthermore, immunohistochemical studies of this case demonstrated ovarian SMBT cells were positive for estrogen receptor, progesterone receptor, and hepatocyte nuclear factor-1beta. A similar expression pattern was also observed in patients with benign OE. LESSONS: In many respects, SMBT characteristics differ from those of EAOC but resemble those of benign OE. MR relaxometry unveils a new clinical approach as an adjunctive modality for discriminating SMBT from EAOC.
format Online
Article
Text
id pubmed-6709009
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67090092019-10-01 A diagnostic challenge of seromucinous borderline tumor: A case report Liu, Tingting Sumida, Daichi Wada, Takuya Maehana, Tomoka Yamawaki, Aika Sugimoto, Sumire Kawahara, Naoki Yoshimoto, Chiharu Kobayashi, Hiroshi Medicine (Baltimore) Research Article INTRODUCTION: Magnetic resonance (MR) relaxometry provides a noninvasive predictive tool to discriminate between benign ovarian endometrioma (OE) and endometriosis-associated ovarian cancer (EAOC). Transverse relaxation rate R2 value was determined using a single-voxel, multi-echo MR sequence (HISTO) by a 3T-MR system. R2 with cutoff value of 12.1 s(−1) was established to discriminate between benign and malignant tumors. PATIENT CONCERNS: We present a case of a 39-year-old woman who was initially thought to be malignant transformation of endometriosis by diagnostic MR imaging of the vascularized solid components. DIAGNOSIS: A R2 value of 42.62 s(−1) on MR relaxometry demonstrated that this case is non-malignant. INTERVENTIONS: To confirm the diagnose, left salpingo-oophorectomy by laparoscopic surgery was performed. OUTCOMES: Histopathological results revealed seromucinous borderline tumor (SMBT). Our experience suggests that preoperative MR relaxometry may be useful for discriminating “borderline (SMBT)” from “malignancy (EAOC).” Furthermore, immunohistochemical studies of this case demonstrated ovarian SMBT cells were positive for estrogen receptor, progesterone receptor, and hepatocyte nuclear factor-1beta. A similar expression pattern was also observed in patients with benign OE. LESSONS: In many respects, SMBT characteristics differ from those of EAOC but resemble those of benign OE. MR relaxometry unveils a new clinical approach as an adjunctive modality for discriminating SMBT from EAOC. Wolters Kluwer Health 2019-05-31 /pmc/articles/PMC6709009/ /pubmed/31145284 http://dx.doi.org/10.1097/MD.0000000000015707 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Liu, Tingting
Sumida, Daichi
Wada, Takuya
Maehana, Tomoka
Yamawaki, Aika
Sugimoto, Sumire
Kawahara, Naoki
Yoshimoto, Chiharu
Kobayashi, Hiroshi
A diagnostic challenge of seromucinous borderline tumor: A case report
title A diagnostic challenge of seromucinous borderline tumor: A case report
title_full A diagnostic challenge of seromucinous borderline tumor: A case report
title_fullStr A diagnostic challenge of seromucinous borderline tumor: A case report
title_full_unstemmed A diagnostic challenge of seromucinous borderline tumor: A case report
title_short A diagnostic challenge of seromucinous borderline tumor: A case report
title_sort diagnostic challenge of seromucinous borderline tumor: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709009/
https://www.ncbi.nlm.nih.gov/pubmed/31145284
http://dx.doi.org/10.1097/MD.0000000000015707
work_keys_str_mv AT liutingting adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT sumidadaichi adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT wadatakuya adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT maehanatomoka adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT yamawakiaika adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT sugimotosumire adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT kawaharanaoki adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT yoshimotochiharu adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT kobayashihiroshi adiagnosticchallengeofseromucinousborderlinetumoracasereport
AT liutingting diagnosticchallengeofseromucinousborderlinetumoracasereport
AT sumidadaichi diagnosticchallengeofseromucinousborderlinetumoracasereport
AT wadatakuya diagnosticchallengeofseromucinousborderlinetumoracasereport
AT maehanatomoka diagnosticchallengeofseromucinousborderlinetumoracasereport
AT yamawakiaika diagnosticchallengeofseromucinousborderlinetumoracasereport
AT sugimotosumire diagnosticchallengeofseromucinousborderlinetumoracasereport
AT kawaharanaoki diagnosticchallengeofseromucinousborderlinetumoracasereport
AT yoshimotochiharu diagnosticchallengeofseromucinousborderlinetumoracasereport
AT kobayashihiroshi diagnosticchallengeofseromucinousborderlinetumoracasereport